Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events
Ist Teil von
The New England journal of medicine, 2016-02, Vol.374 (7), p.625-635
Ort / Verlag
United States: Massachusetts Medical Society
Erscheinungsjahr
2016
Quelle
MEDLINE
Beschreibungen/Notizen
In an effort to reduce the rate of sickle cell crises and acute chest syndrome, a trial compared prasugrel with placebo in patients 2 through 17 years of age who had sickle cell anemia. Prasugrel did not have a significant effect on the rate of vaso-occlusive crises.
Sickle cell anemia, which is estimated to affect 100 million persons worldwide, is an inherited blood disorder characterized by hemolytic anemia and recurrent vaso-occlusive crises that are associated with hospitalizations, impaired quality of life, and early death.
1
–
3
The pathophysiological mechanism of vaso-occlusion in sickle cell anemia is complex. The polymerization of sickle hemoglobin initiates a cascade of thrombotic and inflammatory insults that result in progressive vascular damage and ischemic end-organ injury.
4
Hydroxyurea is partially effective in reducing the frequency of acute vaso-occlusive events, but it has not been shown to prevent organ damage.
5
There is an unmet need for . . .